3 Sleeper Biotechs That Could Bounce Back Strong in 2017
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
2016 was hard for biotech stocks, some more than others. These three present a buy low opportunity.
November 22, 2016: Here are four stocks trading with relatively heavy volume among 38 equities making new 52-week lows in Tuesday’s session. On the NYSE, advancers led decliners by about 2.5 to…
November 18, 2016: Here are four stocks trading with relatively heavy volume among 39 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by nearly 3 to…
November 18, 2016: Here are four stocks trading with relatively heavy volume among 46 equities making new 52-week lows in Friday’s session. On the NYSE, advancers and decliners traded about equally and…
Building on a turn toward more equity investments in the second quarter of this year, the top 50 hedge funds boosted their equity positions by nearly 3% in the third quarter.
November 7, 2016: Here are four stocks trading with relatively heavy volume among 106 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by nearly 5 to…
October 7, 2016: Here are four stocks trading with relatively heavy volume among 26 equities making new 52-week lows in Monday’s session. On the NYSE, advancers led decliners by about 2.5 to…
September 27, 2016: Here are four stocks trading with relatively heavy volume among 43 equities making new 52-week lows in Tuesday’s session. NYSE advancers led decliners by nearly 3 to 2 and Nasdaq…
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Chesapeake Energy, JPMorgan, Melco Crown Entertainment, Navistar, Randgold Resources, Silver Wheaton, Verifone.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Carnival, Ciena, MercadoLibre, Spark Therapeutics, Smith & Wesson, Teva Pharmaceutical and Verifone.
At this point, bad news is coming in consistently to the point that any significant piece of good news could catapult Sanofi stock higher, making it an interesting choice for dip-buyers.
The top analyst upgrades, downgrades and initiations seen on Monday morning include BlackRock, Bristol-Myers, Level 3, NVIDIA, Monsanto and Twenty-First Century Fox.
Janus Capital has now launched the Obesity ETF, which has a strategy of investing in companies that provide treatment and care for obesity and obesity‐related disease.
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.